BACKGROUND: The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). METHODS: Patients with MCL were treated on 2 sequential trials. In Trial 95-80-53, patients received 2-CDA as initial therapy or at relapse. In Trial N0189, patients received combination 2-CDA and rituximab as initial therapy. In both trials, 2-CDA was administered at a dose of 5 mg/m2 intravenously on Days 1 through 5 every 4 weeks for 2 to 6 cycles, depending on response. In Trial N0189, rituximab 375 mg/m2 was administered on Day 1 of each cycle. RESULTS: Results were reported for 80 patients. Twenty-six previously untreated patients and 25 patients who had recurrent disease with a median age of 68 years received single-agent 2-CDA. The overall response rate (ORR) was 81% with 42% complete responses (CRs) in the previously untreated group. The median progression-free survival (PFS) was 13.6 months (95% confidence interval [95% CI], 7.2-22.1 months), and 81% of patients remained alive at 2 years. The ORR was 46% with a 21% CR rate in the recurrent disease group. The median PFS was 5.4 months (95% CI, 4.6-13.1 months), and 36% of patients remained alive at 2 years. Twenty-nine eligible patients with a median age of 70 years received 2-CDA plus rituximab. The ORR was 66% (19 of 29 patient), and the CR rate was 52% (15 of 29 patients). The median duration of response for patients who achieved a CR had not been reached at the time of the current report, and only 3 of the patients who achieved a CR developed recurrent disease at a median follow-up of 21.5 months. CONCLUSIONS: 2-CDA had substantial single-agent activity in both recurrent and untreated MCL, and the results indicated that it may be administered safely to elderly patients. The addition of rituximab to 2-CDA may increase the duration of response. (Copyright) 2008 American Cancer Society.
BACKGROUND: The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). METHODS:Patients with MCL were treated on 2 sequential trials. In Trial 95-80-53, patients received 2-CDA as initial therapy or at relapse. In Trial N0189, patients received combination 2-CDA and rituximab as initial therapy. In both trials, 2-CDA was administered at a dose of 5 mg/m2 intravenously on Days 1 through 5 every 4 weeks for 2 to 6 cycles, depending on response. In Trial N0189, rituximab 375 mg/m2 was administered on Day 1 of each cycle. RESULTS: Results were reported for 80 patients. Twenty-six previously untreated patients and 25 patients who had recurrent disease with a median age of 68 years received single-agent 2-CDA. The overall response rate (ORR) was 81% with 42% complete responses (CRs) in the previously untreated group. The median progression-free survival (PFS) was 13.6 months (95% confidence interval [95% CI], 7.2-22.1 months), and 81% of patients remained alive at 2 years. The ORR was 46% with a 21% CR rate in the recurrent disease group. The median PFS was 5.4 months (95% CI, 4.6-13.1 months), and 36% of patients remained alive at 2 years. Twenty-nine eligible patients with a median age of 70 years received 2-CDA plus rituximab. The ORR was 66% (19 of 29 patient), and the CR rate was 52% (15 of 29 patients). The median duration of response for patients who achieved a CR had not been reached at the time of the current report, and only 3 of the patients who achieved a CR developed recurrent disease at a median follow-up of 21.5 months. CONCLUSIONS:2-CDA had substantial single-agent activity in both recurrent and untreated MCL, and the results indicated that it may be administered safely to elderly patients. The addition of rituximab to 2-CDA may increase the duration of response. (Copyright) 2008 American Cancer Society.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann Journal: Blood Date: 2006-08-31 Impact factor: 22.113
Authors: A Belch; C T Kouroukis; M Crump; L Sehn; R D Gascoyne; R Klasa; J Powers; J Wright; E A Eisenhauer Journal: Ann Oncol Date: 2006-09-13 Impact factor: 32.976
Authors: Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Anna Szmigielska-Kaplon; Krzysztof Chojnowski; Jerzy Z Blonski Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: T E Witzig; C A White; G A Wiseman; L I Gordon; C Emmanouilides; A Raubitschek; N Janakiraman; J Gutheil; R J Schilder; S Spies; D H Silverman; E Parker; A J Grillo-López Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: B S Kahl; W L Longo; J C Eickhoff; J Zehnder; C Jones; J Blank; T McFarland; W Bottner; H Rezazedeh; J Werndli; H H Bailey Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: D S Ritchie; J F Seymour; A P Grigg; A W Roberts; R Hoyt; S Thompson; J Szer; H M Prince Journal: Ann Hematol Date: 2006-11-07 Impact factor: 3.673
Authors: Ajay K Gopal; Joseph G Rajendran; Ted A Gooley; John M Pagel; Darrell R Fisher; Stephen H Petersdorf; David G Maloney; Janet F Eary; Frederick R Appelbaum; Oliver W Press Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: C Nickenig; M Dreyling; E Hoster; W-D Ludwig; B Dörken; M Freund; C Huber; A Ganser; L Trümper; R Forstpointner; M Unterhalt; W Hiddemann Journal: Ann Oncol Date: 2006-10-27 Impact factor: 32.976
Authors: Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2014-09 Impact factor: 11.908
Authors: T E Witzig; C B Reeder; B R LaPlant; M Gupta; P B Johnston; I N Micallef; L F Porrata; S M Ansell; J P Colgan; E D Jacobsen; I M Ghobrial; T M Habermann Journal: Leukemia Date: 2010-12-07 Impact factor: 11.528
Authors: D J Inwards; P A Fishkin; B R LaPlant; M T Drake; P J Kurtin; D A Nikcevich; D B Wender; B S Lair; T E Witzig Journal: Ann Oncol Date: 2014-07-23 Impact factor: 32.976